Therapeutic Potential of MgO and MnO Nanoparticles Within the Context of Thyroid Profile and Pancreatic Histology in a Diabetic Rat Model

Abstract

Magnesium oxide (MgO) and manganese oxide (MnO) have been reported to be effective against Diabetes Mellitus (DM). However, their nanoparticulate form has not been evaluated for antidiabetic effect. MgO and MnO nanoparticles (15–35 nm) were synthesized and subsequently characterized by ultraviolet-visible spectroscopy (UV-VIS), zeta sizer, and scanning electron microscopy. 6–7 weeks old rats weighing 200–220 mg were divided into 07 equal groups (n = 8), namely, negative control (NC), positive control (PC), standard control (Std-C), MgO high dose group (MgO-300) and low dose group (MgO-150), and MnO nanoparticle high dose (MnO-30) and low dose group (MnO-15). Diabetes was chemically induced (streptozotocin 60 mg/kg B.W) in all groups except the NC. Animals were given CMD and water was ad libitum. Nanoparticles were supplemented for 30 days after the successful induction of diabetes. Blood and tissue samples were collected after the 30th day of the trial. The mean serum glucose, insulin, and glucagon levels were improved maximally in the MgO-300 group followed by MgO-150 and MnO-30 groups. Whereas the MnO-15 group fails to show any substantial improvement in the levels of glucose, insulin, and glucagon as compared to the positive control group. Interesting the serum triiodothyronine, thyroxine, and thyroid-stimulating hormone levels were markedly improved in all the nanoparticle treatment groups and were found to be similar to the standard control group. These results highlight the modulatory properties of MgO and MnO nanoparticles and merit further studies delineating the molecular mechanisms through which these nanoparticles induce antidiabetic effects.

Investigation of Immunohistochemical Localization of Oxytocin Receptor in Diabetic and Non-Diabetic Mouse Heart

“…Yeğin and Mert (2013) confirmed mice as diabetic if their blood glucose level was above 210 mg/dL (24), Demir and Yılmaz (2013) accepted mice as diabetic if blood glucose level was between 140-200 mg/dL (25), and Kanitkar and Bhonde (2004) verified mice as diabetic if it was 200 mg/dL. In our study, mice with ≥ 200 mg/dL fasting blood glucose level established as diabetic (19).…”

“…Animals in the diabetic group were fasted for 12-hour to determine 72 hours later blood glucose level. It was considered as diabetic if blood glucose level equal or above 200 mg/dL (19). On the 30 th day of the study, before the tissues were collected, the animals were again fasted for 12 hours and their blood glucose level were measured for the last time.…”

Bioactive Dental Resin Composites with MgO Nanoparticles

“…Previous literature studies have reported that the MgONPs with a particle radius of ∼75 nm have a UV−vis absorption peak at 257 nm and those with a radius of 25−35 nm exhibit a peak at 295 nm, which were much distant from the 163 nm peak observed in bulk MgO. 33,63 The MgONPs utilized in this work was ∼50 nm, and thus its UV−vis absorption peak could fall between 257 and 295 nm. This was much lower than the wavelength of 400−500 nm emitted by the light curing unit.…”

Host insulin resistance caused by Porphyromonas gingivalis-review of recent progresses

“…Studies have suggested that P. gingivalis can contribute to the development of insulin resistance, one proposed mechanism for this effect is through lipotoxicity. Insulin resistance (IR) is associated with lipotoxicity, and chronic inflammation may be a common denominator ( Watanabe et al., 2011 ; Fleetwood et al., 2017 ; Ni et al., 2018 ; Pirih et al., 2021 ; Shaukat et al., 2022 ; Thouvenot et al., 2022 ; Yoshimoto et al., 2022 ). In mice, oral administration of P. gingivalis leads to systemic inflammation, increased adiposity and insulin resistance ( Artese et al., 2015 ; Le Sage et al., 2017 ).…”